

PharmAbcine signs oncology agreement with Binex

03 September 2020 | News

This contract will allow Binex to start the operation of its new 5,000L production line designed for large-scale commercial production.



South Korea based PharmAbcine, a biotech company focusing on the development of antibody therapeutics, has announced on that it has signed a contract manufacturing organization (CMO) agreement with Binex, a leading biologics CDMO (Contract Development and Manufacturing Organization) company in Korea.

With the new contract, Binex will produce Olinvacimab (TTAC-0001), PharmAbcine's leading antibody therapeutics pipeline in oncology, using the new 5,000L production line while it was previously produced in the 1,000L production line. This contract will allow Binex to start the operation of its new 5,000L production line designed for large-scale commercial production.

As for PharmAbcine, this agreement will accommodate timelier and less costly delivery of Olinvacimab for its rapidly expanding list of both clinical and non-clinical studies. The list of studies includes, among others, the global clinical trial for Avastin refractory rGBM (recurrent glioblastoma multiforme) patients, the global combination trial with pembrolizumab for mTNBC (metastatic triple-negative breast cancer), the research collaboration with SLBio in China for non-small cell lung cancer therapeutics, multiple investigator-initiated studies planned for solid tumors, etc.

Dr Jin-San Yoo, CEO of PharmAbcine commented, "We are very pleased with this agreement as Binex has been a very reliable clinical manufacturing partner since the very beginning of the clinical trials. This agreement bodes well with our business strategy of aggressively expanding the indications of our front runner molecule."